Most patients receive antiplatelet treatment after an acute coronary syndrome. Combinations of antiplatelet agents reduce risk of recurrent MI — particularly stent thrombosis — but do have a modest increase in bleeding risk. Well, what about our post-MI patients who are taking appropriately prescribed antiplatelet agents who also require treatment with NSAIDs for disorders like osteoarthritis, migraine, etc? How does such multidrug co-administration affect risks?
The number of men receiving treatment for hypogonadism has increased dramatically over the past decade. At the same time, some clinical trials have suggested that there are safety issues with testosterone.
The relationship between homocysteine and vascular disease has been recognized for at least two decades. Indeed, the strength of the association between plasma hCYS levels and coronary atherosclerosis surpasses that of cholesterol.